Global pharmaceutical giant AstraZeneca announced at the European Society for Medical Oncology annual meeting that combining the targeted cancer drugs osimertinib and savolitinib extends overall survival by roughly five months compared to standard chemotherapy in non-small cell lung cancer patients who developed resistance to initial targeted therapy.
What You Need to Know About the SAFFRON Trial
- Overall survival reached a median of 17.8 months for patients on the dual-drug regimen, compared to 12.9 months for those receiving standard chemotherapy.
- Progression-free survival hit 7.6 months under the combination therapy, versus 5.4 months for the chemotherapy control group.
- Severe adverse events of grade 3 or higher affected 64 percent of the combination group and 63 percent of the chemotherapy group, indicating that careful patient monitoring remains essential.
The Mechanics of Drug Resistance in EGFR-Mutated Lung Cancer
Patients with epithelial growth factor receptor gene mutations rely on targeted therapies like osimertinib, sold under the brand name Tagrisso, to block growth signals driving tumor proliferation. Over time, however, cancer cells adapt. They frequently upregulate or amplify the MET protein to bypass the blocked pathway and restart cell growth. Kormedi.com reported that this resistance renders single-agent therapy ineffective, leaving clinicians searching for secondary options to suppress tumor advancement.
Evaluating the Combination of Osimertinib and Savolitinib
To tackle this specific resistance mechanism, researchers designed the phase 3 trial known as SAFFRON. The study enrolled 338 non-small cell lung cancer patients whose tumors progressed on osimertinib and exhibited MET overexpression or gene amplification. Investigators administered a dual oral regimen pairing osimertinib with the MET inhibitor savolitinib, marketed as Opasys. By simultaneously shutting down two separate tumor survival pathways, the combination dropped the risk of disease progression or death by 45 percent, while lowering the risk of death alone by 32 percent.
China Approves Combination Therapy for Lung Cancer Patients
Regulatory pathways have already moved faster in other regions. China approved the combination therapy for specific EGFR-mutated and MET-altered lung cancer patients based on earlier phase 3 data.
| Metric | Combination Therapy (Osimertinib + Savolitinib) | Standard Chemotherapy |
|---|---|---|
| Overall Survival Median | 17.8 months | 12.9 months |
| Progression-Free Survival Median | 7.6 months | 5.4 months |
| Risk of Disease Progression or Death | 45% reduction | Baseline |
| Severe Adverse Events (Grade 3+) | 64% | 63% |
Trial Outcomes Apply to Patients with Specific Mutations
AstraZeneca emphasized that the trial outcomes apply exclusively to patients carrying specific EGFR mutations alongside MET alterations identified after initial osimertinib treatment. The findings do not extend to the broader population of all lung cancer patients. The high incidence of severe side effects across both trial arms means clinicians must closely supervise patients on these potent multi-drug regimens.
AstraZeneca $AZN and China's Hutchmed said that a late-stage trial of a combination of their cancer drugs Tagrisso and Orpathys significantly improved progression-free survival when given early for a type of lung cancer. Cancer therapies make up nearly half of AstraZeneca's…
Worth a look
- Andy Weir Pitches Star Trek and Star Wars Crossover
- Why We Love Horror: Fans Discuss the Movies That Still Scare Them
- Firefighting Volunteers in Banjar Perform Grateful Prayer as Rain Ends Months of Wildfires (archynewsy.com)
- How to Choose the Best ABA Therapy in Raleigh and Durham (world-today-news.com)
